Ribavirin has also been used in attempts to treat various DNA and RNA virus infections, although acquired resistance to the drug has been demonstrated in various virus populations and in some patients [29]. The development of antiviral drugs targeting viruses classified in the Picornaviridae family is therefore urgently required. In the current study, the antiviral activities of ginsenosides against CVB3, EV71, and HRV3 have been evaluated and compared with the currently used antiviral drug ribavirin, which exhibits some antiviral activity. The results of our study demonstrating the antiviral activities of ginsenosides suggest that the compounds may provide a therapeutic option for the treatment of CVB3, EV71, and HRV3

infection; Compound C datasheet furthermore, the compounds could potentially be effective against Picornaviridae viruses in general. Strong anti-CVB3 and anti-HRV3 activity was demonstrated for PT-type ginsenosides (Re, Rf, and Rg2), ATR inhibitor and ginsenoside Rg2 of the PT type showed anti-EV71 activity, despite its relatively weak activity. By contrast, PD-type ginsenosides (Rb1, Rb2, Rc, and Rd) did not show

any antiviral activity against CVB3, EV71 and HRV3, and even increased the cytotoxicity induced by virus infection. Taken together, these results indicate that the antiviral activities of ginsenosides against CVB3, EV71, and HRV3 appear to be selectively dependent on the type of ginsenosides. Ginsenoside is divided into PD saponin and PT saponin by its chemical structure. The other study group investigated and compared the antiobesity activity of PD-type and PT-type saponins in rats fed a high fat diet. In conclusion, PD- and PT-type saponins have been shown to exert antiobesity effects in the rats fed with a high fat diet by reducing their body weight, their food consumption, and their fat storage. However, PD-type saponins

have more potent antiobesity properties than PT-type saponins [41]. We think our data also demonstrate that antiviral activities are related to the chemical structures. Therefore, further studies are required to explore the detailed antiviral mechanisms of ginsenosides Cell press of the PT type as well as to assess in vivo antiviral activity. The authors declare that they have no competing interests. CVB3 and EV71 were provided by Chungcheongnam-Do Health and Environment Research Institute, Daejeon, South Korea. We also thank Dr Kwi-Sung Park for providing CB3 and EV71. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korean Ministry of Education, Science and Technology (NRF-2012R1A1A2003182). This study was technically supported by Korea National Institute of Health. This research was supported by 2013 Research Grant from Kangwon National University (No. 120131474/C1009934-01-01) and by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (No.